Value Sense
HSCS
Heart Test Laboratories, Inc. (HSCS)
Last Price$2.95.0%
Market Cap$2,541.3M
LTM EBITDA
($1,990.4M)
YoY Growth
+34,336.3%
3Y CAGR
+875.0%
5Y CAGR
+380.1%
Stock quality & Intrinsic value
5/10
11,448.4% undervalued
HSCS
is 11,448.4% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Heart Test Laboratories, Inc. EBITDA

Annual
Quarterly
LTM
Crunching data... Almost there!
Apr'20Apr'21Apr'22Apr'23Apr'24
EBITDA
($3,744.5K)
($2,286.1K)
($4,430.1K)
($6,084.2K)
($6,156.0K)
HSCS
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for HSCS and see if it's the right time to invest.
Dive in

Heart Test Laboratories, Inc. (HSCS) EBITDA comparison analysis

General

LTM EBITDA

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Heart Test Laboratories, Inc. logo
Heart Test Laboratories, Inc.HSCS
($1,990.4M)
34,336.3%
875.0%
N/A
Median Peer Set
$2,118.7M
5.8%
9.9%
7.0%
Abbott Laboratories logo
Abbott LaboratoriesABT
$10.9B
4.8%
(6.4%)
6.8%
Medtronic plc logo
Medtronic plcMDT
$9,392.0M
4.7%
(0.8%)
(0.7%)
Stryker Corporation logo
Stryker CorporationSYK
$5,716.0M
14.4%
7.2%
6.5%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
$3,863.0M
12.0%
15.3%
15.8%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
$2,423.4M
(1.0%)
12.7%
(0.1%)
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
$1,814.0M
6.8%
1.3%
7.3%
STERIS plc logo
STERIS plcSTE
$1,227.3M
(13.7%)
12.6%
11.2%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
$1,076.4M
102.9%
(6.7%)
(15.2%)
DexCom, Inc. logo
DexCom, Inc.DXCM
$914.1M
(0.3%)
34.1%
33.8%
Insulet Corporation logo
Insulet CorporationPODD
$443.2M
39.6%
47.0%
42.1%

HSCS key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Apr'20Apr'21Apr'22Apr'23Apr'24
Revenue
% growth
0.1
0.0%
0.0
(60.1%)
0.0
(43.9%)
0.0
(64.2%)
0.0
261.2%
Cost of Goods Sold (COGS)0.00.00.00.00.0
Gross Profit
% margin
0.0
27.6%
0.0
58.3%
0.0
45.1%
0.0
45.7%
0.0
67.3%
Operating Expenses3.82.64.76.16.3
Research & Development Expenses (R&D)2.01.73.02.52.9
Selling, General & Administrative Expenses (SG&A)1.80.91.73.73.4
Operating Income
% margin
(3.8)
(5,949.0%)
(2.6)
(10,030.2%)
(4.7)
(32,765.6%)
(6.1)
(118,698.3%)
(6.3)
(33,902.0%)
Interest Income0.00.10.40.20.0
Interest Expense0.00.10.40.20.4
Pre-tax Income(3.8)(2.5)(4.8)(6.4)(6.6)
Income Tax
% effective tax rate
0.0
(0.6%)
0.1
(5.3%)
(0.3)
5.2%
484.5
(7,624.8%)
0.0
0.0%
Net Income
% margin
(3.8)
(5,973.4%)
(2.6)
(10,081.1%)
(4.6)
(31,851.8%)
(490.9)
(9,531,151.3%)
(6.6)
(35,511.9%)
EPS(115.69)(77.89)(137.94)(6,173.88)(18.74)
Diluted EPS(115.69)(77.89)(137.94)(6,173.88)(18.74)
EBITDA
% margin
(3.7)
(5,834.2%)
(2.3)
(8,928.7%)
(4.4)
(30,822.2%)
(6.1)
(118,139.8%)
(6.2)
(33,096.7%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Heart Test Laboratories, Inc.'s EBITDA?

As of today, Heart Test Laboratories, Inc.'s last 12-month EBITDA is ($1,990.4M), based on the financial report for Oct 31, 2024 (Q4’2024).

2) What is Heart Test Laboratories, Inc.'s EBITDA growth rate?

Over the last year, Heart Test Laboratories, Inc.'s EBITDA growth was 34,336.3%. The average annual EBITDA growth rates for Heart Test Laboratories, Inc. have been 1,266.4% over the past three years, 380.1% over the past five years.

3) Is Heart Test Laboratories, Inc.'s EBITDA growth rate Good?

Over the last year, Heart Test Laboratories, Inc.'s EBITDA growth was 34,336.3%, which is higher than industry growth of (0.3%). It indicates that Heart Test Laboratories, Inc.'s EBITDA growth is Good.

4) How does Heart Test Laboratories, Inc.'s EBITDA growth rate compare to its peers?

Over the last year, Heart Test Laboratories, Inc.'s EBITDA growth was 34,336.3%, which is higher than peer median growth of 2.2%. The list of peers includes ABT, MDT, SYK, BSX, ZBH, EW, STE, PHG, DXCM, PODD etc.